Which Vaccines Could Help Control the Ebola Epidemic? WHO in Discussion

Overview

The WHO is evaluating potential vaccines and therapeutics to combat the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo. Current options include remdesivir and monoclonal antibodies, while the use of existing vaccines is under careful consideration.

Background

The ongoing Ebola outbreak in the Democratic Republic of the Congo represents a significant public health challenge, particularly as it involves the rare Bundibugyo strain. With no approved vaccines or therapeutics specifically for this strain, the urgency for effective interventions is critical. The WHO's discussions highlight the need for clinical trials to assess the efficacy of potential treatments and vaccines.

Data Highlights

Currently, there are no approved vaccines for the Bundibugyo species of Ebola. The WHO suggests prioritizing clinical trials for Gilead’s remdesivir and monoclonal antibodies MBP134 and Maftivimab.

Key Findings

• The WHO recommends testing Gilead’s antiviral obeldesivir for preventing disease in exposed individuals.
• Bundibugyo-specific vaccines are not available and will take months to develop.
• Merck’s Ervebo vaccine may provide cross-protection, but its use is restricted to clinical trials.
• The current outbreak is the third-largest on record, with significant cases reported in both DRC and Uganda.
• Health experts criticize the U.S. decision to evacuate Ebola patients to Europe instead of utilizing domestic facilities.

Clinical Implications

Healthcare professionals should be aware of the ongoing discussions regarding the use of existing antiviral treatments and the need for clinical trials for new vaccines. The situation underscores the importance of preparedness and rapid response in managing Ebola outbreaks.

Conclusion

The WHO's evaluation of potential vaccines and treatments is crucial in addressing the current Ebola outbreak. Continued research and clinical trials will be essential for effective intervention strategies.

Related Resources & Content

1. Kaiser Family Foundation (KFF), Is The U.S. Stepping Up In The Fight Against Ebola?, 2023
2. conexiant, Rare Ebola Strain Sparks Global Alert, 2023
3. Stat News, Ebola at the World Cup? Here’s what we should actually worry about, 2023
4. WHO, Ebola virus disease vaccines, 2023
5. The Journal of Infectious Diseases — Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus Disease
6. WHO, Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization on Ebola vaccination, May 2024
7. CDC, Ebola Vaccine Product Information
8. Ebola virus disease vaccines
9. https://cdn.who.int/media/docs/default-source/immunization/sage/2024/may/summary-of-findings-ebola-vaccine-20231204.pdf?sfvrsn=6c9942d8_1
10. Emergency stockpile availability report - Ebola vaccine | UNICEF Supply Division
11. Ebola vaccine stockpiles
12. CORE Protocol - A phase 1/2/3 study to evaluate the safety, tolerability, immunogenicity, and efficacy of vaccine candidates against (Filoviruses) virus disease in healthy individuals at risk of (Filovirus) virus disease
13. Groundbreaking Ebola vaccination trial launches today in Uganda